

1 **Adjusting for specificity of symptoms reveals higher prevalence of asymptomatic SARS-**
2 **CoV-2 infections than previously estimated**

3

4 Akshay Tiwari¹, Shreya Chowdhury¹, Ananthu James^{1,§}, Budhaditya Chatterjee^{2,#}, Narendra M.
5 Dixit^{1,2,*}

6 ¹Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012

7 ²Department of Bioengineering, Indian Institute of Science, Bangalore, India 560012

8 [§]Current address: Department of Public Health, Erasmus MC, University Medical Center
9 Rotterdam, Rotterdam, The Netherlands

10 [#]Current address: Department of Microbiology and Immunology, School of Medicine, University
11 of Maryland Baltimore, Baltimore, MD, USA and NIAID, NIH, Bethesda, MD, USA

12 *Correspondence: narendra@iisc.ac.in

13

14 **Manuscript details:**

15 Title: 127 characters; Abstract: 232 words; Text: ~2000 words; Figure: 1; References: 74

16 Supplementary Information: Table: 1; Figure: 1

17

18 ABSTRACT

19 Accurate estimates of the prevalence of asymptomatic SARS-CoV-2 infections, ψ , have been
20 important for understanding and forecasting the trajectory of the COVID-19 pandemic. Two-part
21 population-based surveys, which test the infection status and also assess symptoms, have been
22 used to estimate ψ . Here, we identified a widely prevalent confounding effect that compromises
23 these estimates and devised a formalism to adjust for it. The symptoms associated with SARS-
24 CoV-2 infection are not all specific to SARS-CoV-2. They can be triggered by a host of other
25 conditions, such as influenza virus infection. By not accounting for the source of the symptoms,
26 the surveys may misclassify individuals experiencing symptoms from other conditions as
27 symptomatic for SARS-CoV-2, thus underestimating ψ . We developed a rigorous formalism to
28 adjust for this confounding effect and derived a facile formula for the adjusted prevalence, ψ_{adj} .
29 We applied it to data from 50 published serosurveys, conducted on the general populations from
30 28 nations. We found that ψ_{adj} was significantly higher than the reported prevalence, ψ_c
31 ($P=3\times 10^{-8}$). The median ψ_{adj} was $\sim 60\%$, whereas the median ψ_c was $\sim 40\%$. In several
32 instances, ψ_{adj} exceeded ψ_c by $>100\%$. These findings suggest that asymptomatic infections
33 have been far more prevalent than previously estimated. Our formalism can be readily deployed
34 to obtain more accurate estimates of ψ from standard population-based surveys, without
35 additional data collection. The findings have implications for understanding COVID-19
36 epidemiology and devising more effective interventions.

37

38 INTRODUCTION

39 Asymptomatic SARS-CoV-2 infections have been a major contributor to the spread of the
40 COVID-19 pandemic, with nearly a quarter of all transmission events attributed to them¹. They
41 also represent a key outcome of COVID-19 vaccination; vaccine efficacies have been estimated
42 as the fraction of potentially symptomatic infections rendered asymptomatic by vaccination in
43 clinical trials²⁻⁴. Accurate estimation of the prevalence of asymptomatic infections, ψ , is thus
44 important for understanding COVID-19 epidemiology and for designing and assessing public
45 health interventions. A large number of surveys, conducted throughout the pandemic, have
46 offered estimates of ψ ^{5,6}. Here, we recognized an important confounding factor that
47 compromises these estimates and devised a formalism to adjust for it.

48 The surveys contain two parts: 1) a nucleic acid or an antibody test to detect SARS-CoV-2
49 infection, and 2) a questionnaire to assess the symptoms experienced. Individuals who test
50 positive for the infection but declare no symptoms are deemed asymptotically infected. ψ is
51 thus estimated as the fraction of test-positive cases that reports no symptoms. The confounding
52 effect arises from the symptoms assessed not being specific to COVID-19. Symptoms such as
53 cough and fever, which are part of nearly all COVID-19 surveys, can be triggered not only by
54 SARS-CoV-2 infection but also by a host of other infections including influenza and circulating
55 coronaviruses. It is possible, therefore, that some individuals who reported symptoms in the
56 surveys may have had them due to the other conditions. Such individuals should be classified
57 as asymptomatic for SARS-CoV-2 but get misclassified as symptomatic, resulting in a systematic
58 underestimation of ψ .

59 Evidence of this misclassification exists in the data gathered by the surveys: The surveys identify
60 individuals who test negative for SARS-CoV-2 but report symptoms. For instance, a survey from
61 The Netherlands reported that ~62% of the individuals who tested negative for SARS-CoV-2
62 displayed symptoms⁷. The number was as high as 80% in a survey in the US^{8,9}. These
63 individuals must have had their symptoms arise from causes other than SARS-CoV-2 infection.
64 The high prevalence of such individuals in these surveys implies that at least some of the test-
65 positive, symptomatic cases may have had their symptoms arise from non-COVID conditions.
66 Adjusting for this confounding effect is important to obtain accurate estimates of ψ .

67 The adjustment is challenging because of the two-part survey methodology, with the tests used
68 in the first part, to assess SARS-CoV-2 infection, limited by their own sensitivities and
69 specificities. Thus, the test-negative, symptomatic individuals, discussed above, may not all
70 have been uninfected; some who had the infection may have been classified as test-negative
71 because the antigen (or antibody) levels in them were below assay detection limits. Indeed, the
72 symptoms they experienced may well have arisen from SARS-CoV-2 infection. Thus, the
73 adjustment for the non-specificity of the symptoms must also simultaneously account for the
74 sensitivity and specificity of the SARS-CoV-2 test. Here, we developed a formalism that
75 accomplished that. We applied our formalism to data from 50 published serosurveys, conducted
76 in 28 countries across continents, and found that the adjusted ψ was significantly higher than
77 previously reported. Indeed, in several instances, the previous estimates had to be revised
78 upward by over 100%.

79

80 RESULTS

81 Formalism to adjust for symptom specificity

82 We developed our formalism for the general scenario where the goal is to estimate the
83 prevalence of asymptomatic infections caused by a pathogen of interest when another pathogen
84 that could trigger similar symptoms is also circulating in the population, confounding the
85 estimates. We assumed that data relating to the pathogen of interest was gathered following the
86 two-part survey methodology described above. The detailed derivation is presented in Methods.
87 Here, we let the pathogen of interest be SARS-CoV-2 and the other pathogen represent the
88 collection of all other conditions with symptoms that overlap with those of SARS-CoV-2 infection.
89 Remarkably, we obtained a closed-form expression for the adjusted prevalence of asymptomatic
90 SARS-CoV-2 infections, ψ_{adj} :

$$91 \quad \psi_{adj} = 1 - \frac{\rho_c(1 - \rho_c)(\psi_c - 1 + \phi_c)(\alpha + \beta - 1)}{(\rho_c + \beta - 1)[\psi_c\rho_c(1 - \alpha) - \alpha(1 - \phi_c)(1 - \rho_c)]} \quad (1)$$

92 Here, α and β are the SARS-CoV-2 test sensitivity and specificity, respectively, ψ_c is the crude
93 (or unadjusted) prevalence of asymptomatic cases among test-positive individuals, ρ_c is the
94 crude fraction of test-positive cases among the sampled individuals, and ϕ_c is the crude
95 proportion of symptomatic cases among test-negative individuals. Thus, given the set of
96 quantities $S = \{\alpha, \beta, \rho_c, \phi_c, \psi_c\}$, all of which are typically reported in surveys, ψ_{adj} can be readily
97 calculated.

98 Adjusted estimates of ψ from serosurveys


99 To apply our formalism, we collated data from published serosurveys (Table S1)⁷⁻⁵⁶. Although
100 our method applies also to surveys using nucleic acid-based (PCR) testing, serosurveys have
101 been preferred for assessing asymptomatic SARS-CoV-2 infections because nucleic acid-based
102 testing could miss presymptomatic individuals, who do not display symptoms at the time of
103 testing but develop them later^{5,57}. Serosurveys seek symptoms experienced during a longer
104 'recall period', which renders them more susceptible to confounding from other conditions with
105 overlapping symptoms, highlighting the need for the present adjustment.

106 We considered serosurveys in the early phase of the pandemic, before vaccination programs
107 began, to eliminate any confounding effect of symptoms elicited by vaccines. We restricted our
108 analysis to studies with a sample size of ≥ 500 , as smaller datasets could introduce significant
109 uncertainties in our calculations⁵⁸. We excluded studies on samples biased by symptom status,
110 such as hospitalized patients or long-term care facilities, and focused instead on studies
111 sampling the general population. We, of course, also excluded studies that did not provide all
112 the quantities in S required for the adjustment. With these criteria, we identified 50 serosurveys
113 that were amenable to our analysis. Three of these studies^{13,39,56} estimated ψ at three different
114 time points, resulting in a total of 56 estimates of ψ (Table S1). The selected studies spanned 28
115 countries across Asia, the Americas, Europe, and Africa, covering a broad spectrum of
116 epidemiological settings.

117 To first assess the prevalence and scale of the confounding effect due to the non-specificity of
118 symptoms, we examined the fraction, ϕ_c , of seronegative individuals who reported symptoms
119 across the surveys. ϕ_c varied from 0 to 0.8 with a median of 0.31 (Figure 1A), indicating that
120 overlapping symptoms commonly arose from other conditions and could therefore significantly
121 affect estimates of ψ . Furthermore, although most surveys employed antibody tests with high

122 sensitivity and specificity, several reported sensitivities ≤ 0.85 (Table S1), potentially amplifying
123 the confounding effect.

124



125

126 **Figure 1. Adjusted estimates of the prevalence of asymptomatic SARS-CoV-2 infections**
127 **are higher than crude estimates.** Distributions of (A) fraction of test-negative individuals
128 showing symptoms, ϕ_c , and (B) crude seroprevalence, ρ_c , from 50 serosurveys. (C)
129 the corresponding distributions of the reported crude prevalence of asymptomatic infections,
130 ψ_c (orange), and the adjusted prevalence, ψ_{adj} (red), the latter obtained using equation (1).
131 The dashed lines in (A)-(C) are medians. (D) Individual estimates of ψ_{adj} versus ψ_c . Error
132 bars indicate 95% confidence intervals calculated using the Wilson's score interval⁵⁹. (E)
133 Histogram of the number of surveys with η , the percentage increase of ψ_{adj} over ψ_c , in the
134 ranges shown. The correlations between η and (F) ϕ_c , and (G) test-specificity, β . r_s denotes
135 Spearman's correlation coefficient.

136

137 The crude seroprevalence, ρ_c , varied from 0.01 to 0.58 across the studies, with a median of 0.11,
138 representing a wide range of the extent of spread of the infection in the populations studied at
139 the time of the surveys (Figure 1B).

140 The surveys reported widely varying estimates of the crude prevalence of asymptomatic
141 infections, ψ_c , spanning the range from 0.068 to 1 with a median of 0.40 (Figure 1C, orange).
142 Using equation (1), we calculated the adjusted prevalence, ψ_{adj} , for all the 56 estimates of ψ_c .
143 ψ_{adj} varied from 0.04 to 1.00 with a median of 0.60 (Figure 1C, red). We found overall that ψ_{adj}
144 was significantly larger than ψ_c ($P=3\times 10^{-8}$ using the Wilcoxon signed rank test; Figure 1D). We
145 defined $\eta = 100 \times (\psi_{adj} - \psi_c)/\psi_c$ as the percentage increase in ψ due to the adjustment. Out
146 of the 56 estimates, 9 had $\eta > 100\%$, 10 had η in the range of 50-100%, 12 in the range 25-50%,
147 21 between 0% and 25%, and 4 had $\eta < 0\%$ (Figure 1E).

148 Factors contributing to the adjustment

149 To identify the quantities in S most responsible for the adjustment in the datasets we considered,
150 we calculated pairwise correlations of η with each quantity in S . We found that ϕ_c was strongly
151 positively correlated with η (Spearman's coefficient $r_s = 0.86$, $P < 10^{-16}$) (Figure 1F). β showed a
152 moderate positive correlation with η ($r_s = 0.30$, $P = 0.026$) (Figure 1G). The other quantities were
153 not significantly correlated with η (Figure S1). Thus, the non-specificity of the symptoms was the
154 major contributor to the adjustment. Indeed, for the 9 estimates with $\eta > 100\%$, ϕ_c was $> 50\%$.

155 Our expression in equation (1) reduced when $\alpha = \beta = 1$ to $\psi_{adj} = \frac{\psi_c}{1-\phi_c}$, showing how ϕ_c would
156 contribute to the adjustment even with a perfect antibody test and explaining the positive
157 correlation between ψ_{adj} and ϕ_c . For imperfect antibody tests, where $\alpha < 1$ and/or $\beta < 1$,
158 ψ_{adj} displayed a more complex dependency on the quantities in S (equation (1)). In the absence
159 of symptom overlap ($\phi_c = 0$), equation (1) reduced to $\psi_{adj} = 1 - \frac{\rho_c(1-\rho_c)(\psi_c-1)(\alpha+\beta-1)}{(\rho_c+\beta-1)[\psi_c\rho_c(1-\alpha)-\alpha(1-\rho_c)]}$,
160 allowing ψ_{adj} to be larger or smaller than ψ_c depending on the specific values of α , β , and ρ_c .
161 When $\alpha = 1$, for instance, $\psi_{adj} = 1 - (1 - \psi_c) \frac{\rho_c\beta}{\rho_c+\beta-1} < \psi_c$. (The latter inequality follows
162 because $(1 - \beta)(1 - \rho_c) > 0$ and hence $\frac{\rho_c\beta}{\rho_c+\beta-1} > 1$.) Indeed, the reduction in ψ due to imperfect
163 test sensitivity and specificity may dominate the increase due to overlapping symptoms,
164 explaining the few instances with $\eta < 0\%$ above. Nonetheless, in all but 4 of the 56 instances we
165 studied, we found $\psi_{adj} \geq \psi_c$, highlighting the dominant effect of the adjustment due to symptom
166 overlap.

167 We conclude therefore that ψ has been substantially underestimated by existing serosurveys,
168 primarily due to the confounding effect of the non-specificity of the symptoms elicited by SARS-
169 CoV-2. Our formalism enables adjusting for this effect and arriving at more accurate estimates
170 of ψ .

171

172 DISCUSSION

173 Our formalism makes important advances in addressing confounding effects in the estimation of
174 ψ . A general formalism to adjust for antibody (or nucleic acid) test sensitivity and specificity was

175 developed earlier⁶⁰, which has been applied to obtain accurate SARS-CoV-2 prevalence
176 estimates during the pandemic⁷. The formalism has been extended to estimate ψ , but without
177 accounting for the specificity of the symptoms⁴⁶. The importance of symptom specificity has been
178 recognized earlier: For instance, an increase in the proportion of asymptomatic cases of
179 influenza virus infection resulted after accounting for overlapping symptoms caused by other
180 infections^{61,62}. The adjustment in the latter studies, which relied on regression techniques, did
181 not account, however, for the infection test sensitivity and specificity. Here, we accounted for the
182 infection test sensitivity and specificity as well as the specificity of the symptoms. Furthermore,
183 we derived a closed-form expression for the adjustment (equation (1)) which enables facile
184 application of our formalism.

185 We foresee several implications of our study. First, the refined estimates of ψ that our formalism
186 yields would help reassess the contribution of asymptomatic infections to COVID-19
187 transmission and spread^{1,63}. They would also form inputs to models of COVID-19
188 epidemiology⁶⁴⁻⁶⁶, enabling more reliable forecasting of disease spread and the design of
189 effective control strategies. Second, the formalism could aid COVID-19 vaccine development
190 efforts⁶⁷ by enabling more accurate estimation of vaccine efficacies, which are often based on
191 comparing estimates of ψ in the vaccinated and unvaccinated arms of clinical trials²⁻⁴. Third,
192 estimates of ψ will inform efforts underway to unravel genetic, immunological, and demographic
193 underpinnings of asymptomatic infections⁶⁸⁻⁷². Finally, we anticipate our formalism to be
194 applicable to settings beyond COVID-19 that involve asymptomatic infections, such as
195 influenza^{61,62}. It would be particularly important to epidemiological studies that employ extended
196 symptom recall periods, which increase the likelihood of contracting other infections during the
197 recall period and, consequently, the confounding effect of symptom overlap.

198 Our study has limitations. First, we assumed that symptoms caused by SARS-CoV-2 and by
199 other infections are independent. While co-infection can potentially influence the severity of
200 SARS-CoV-2 infection, such instances appear rare⁷³. Further justification of our assumption
201 comes from studies that found influenza vaccination not to offer significant protection against
202 SARS-CoV-2 symptoms⁷⁴. Second, our selection of serosurveys is not exhaustive. Our aim was
203 to demonstrate the wide applicability and relevance of our formalism and not to provide a global
204 estimate of ψ . Future studies may conduct a more systematic search and meta-analysis using
205 our formalism to obtain such a global estimate of ψ .

206

207 **METHODS**

208 **Formalism to adjust for specificity of symptoms**

209 We consider the scenario where infection by the pathogen of interest, denoted X , can trigger
210 symptoms that may also be triggered by other pathogens (or conditions), the latter collectively
211 denoted Y . Surveys aim to assess the prevalence of asymptomatic infections by X . A test, de-
212 noted T , assesses whether an individual undertaking the test is infected by X . Simultaneously, a
213 questionnaire inquires into the symptoms, denoted S , experienced by the individual during a pre-
214 defined recall period. We recognize that the symptoms may also be triggered by Y . We distin-
215 guish between these possibilities by letting S_X and S_Y represent events associated with the symp-
216 toms being triggered by X and Y , respectively. The aim is to estimate the fraction of individuals

217 infected by X who do not experience symptoms triggered by X . We arrive at this estimate as
218 follows.

219 We define $P[X^+]$ and $P[T^+]$ as the probability with which an individual is infected by X and the
220 probability that the infection test yields a positive result, respectively. Clearly, $P[T^+] = \rho_c$, the
221 crude prevalence estimated by the survey as the fraction of individuals tested who show a posi-
222 tive result. $P[X^+] = \rho_{adj}$ is the actual prevalence, obtained after adjusting for test sensitivity and
223 specificity. The test sensitivity is $\alpha = P[T^+|X^+]$, the probability of the test yielding a positive result
224 given the infection by X . The test specificity is $\beta = P[T^-|X^-]$, the probability that the test yields
225 a negative result, given that the tested individual is not infected by X . The total probability of the
226 test yielding a positive result can thus be written as

$$227 \quad P[T^+] = P[T^+|X^+]P[X^+] + P[T^+|X^-]P[X^-] \quad (2)$$

228 Recognizing that $P[T^+|X^+] = 1 - P[T^-|X^-]$ and $P[X^-] = 1 - P[X^+]$ and substituting the defini-
229 tions above in equation (2), it follows that

$$230 \quad \rho_{adj} = \frac{\rho_c + \beta - 1}{\alpha + \beta - 1} \quad (3)$$

231 We next consider events related to the occurrence of symptoms. The crude prevalence of
232 asymptomatic individuals, $\psi_c = P[S^-|T^+]$, is the probability that an individual who tests positive
233 reports no symptoms. It is thus measured in the surveys as the fraction of test-positive cases
234 who declare no symptoms. Accounting for the test sensitivity and specificity, we again write,

$$235 \quad P[S^-|T^+] = P[S^-|X^+]P[X^+|T^+] + P[S^-|X^-]P[X^-|T^+] \quad (4)$$

236 which, upon recognizing that $P[X^-|T^+] = 1 - P[X^+|T^+]$ and invoking Bayes' theorem,

$$237 \quad P[X^+|T^+] = \frac{P[T^+|X^+]P[X^+]}{P[T^+]} = \frac{\alpha\rho_{adj}}{\rho_c} \quad (5)$$

238 yields

$$239 \quad \psi_c = P[S^-|X^+] \frac{\alpha\rho_{adj}}{\rho_c} + P[S^-|X^-] \left(1 - \frac{\alpha\rho_{adj}}{\rho_c}\right) \quad (6)$$

240 Given the simultaneous presence of X and Y in circulation, the absence of symptoms implies
241 the absence of symptoms triggered by both X and Y . In other words, $\{S^-\} = \{S_X^-\} \cap \{S_Y^-\}$. This
242 yields,

$$243 \quad P[S^-|X^+] = P[S_X^-|X^+]P[S_Y^-|X^+] \quad (7)$$

244 where $P[S_X^-|X^+] = \psi_{adj}$ is the probability that an individual infected by X does not experience
245 symptoms triggered by X , which is the adjusted prevalence of asymptomatic infections, the key
246 quantity of interest here.

247 Similarly, in the absence of infection by X , we may write

$$248 \quad P[S^-|X^-] = P[S_X^-|X^-]P[S_Y^-|X^-] = P[S_Y^-|X^-] \quad (8)$$

249 where the latter equality follows from $P[S_X^-|X^-] = 1$; an individual not infected by X cannot have
250 symptoms triggered by X .

251 Combining equations (6) – (8) yields

$$252 \quad \psi_c = \psi_{adj} P[S_Y^-|X^+] \frac{\alpha \rho_{adj}}{\rho_c} + P[S_Y^-|X^-] \left(1 - \frac{\alpha \rho_{adj}}{\rho_c}\right) \quad (9)$$

253 We next assume that experiencing symptoms triggered by Y or not is independent of infection
254 by X , so that

$$255 \quad P[S_Y^-|X^+] = P[S_Y^-|X^-] \quad (10)$$

256 To estimate the latter probabilities, we invoke their relationship with test results as follows. We
257 recognize that $\omega_c = P[S^-|T^-]$ is the probability of not experiencing symptoms given test-negative
258 status, which represents the crude proportion of asymptomatic cases among test-negative indi-
259 viduals. Following the arguments above, the symptoms must arise neither from X nor Y , so that

$$260 \quad \omega_c = P[S^-|T^-] = P[S_X^-|T^-] P[S_Y^-|T^-] \quad (11)$$

261 Invoking test sensitivity and specificity, we write the first term on the right hand side of equation
262 (11) as

$$263 \quad \begin{aligned} P[S_X^-|T^-] &= P[S_X^-|X^+] P[X^+|T^-] + P[S_X^-|X^-] P[X^-|T^-] \\ &= \psi_{adj} P[X^+|T^-] + (1 - P[X^+|T^-]) \end{aligned} \quad (12)$$

264 where the latter equality follows because $P[S_X^-|X^-] = 1$ and $P[X^-|T^-] = 1 - P[X^+|T^-]$. Using
265 Bayes' theorem and the definitions of the quantities above, we obtain

$$266 \quad P[X^+|T^-] = \frac{P[T^-|X^+] P[X^+]}{P[T^-]} = \frac{(1 - \alpha) \rho_{adj}}{1 - \rho_c} \quad (13)$$

267 Combining equations (11) – (13) and rearranging terms yields

$$268 \quad P[S_X^-|T^-] = \psi_{adj} \frac{(1 - \alpha) \rho_{adj}}{1 - \rho_c} + \frac{1 - \rho_c - \rho_{adj} + \alpha \rho_{adj}}{1 - \rho_c} \quad (14)$$

269 Following a similar procedure, we write the second term on the right hand side of equation
270 (11) as

$$271 \quad P[S_Y^-|T^-] = P[S_Y^-|X^+] P[X^+|T^-] + P[S_Y^-|X^-] (P[X^-|T^-]) = P[S_Y^-|X^+] \quad (15)$$

272 where the latter equality follows because $P[S_Y^-|X^+] = P[S_Y^-|X^-]$ and $P[X^+|T^-] = 1 - P[X^-|T^-]$.
273 Combining equations (14) and (15) with equation (11) and rearranging terms, we obtain

$$274 \quad P[S_Y^-|X^+] = \frac{\omega_c (1 - \rho_c)}{(\psi_{adj} - 1) (1 - \alpha) \rho_{adj} + 1 - \rho_c} \quad (16)$$

275 Finally, combining equations (9), (10), (11), and (16), and letting $\phi_c = 1 - \omega_c$, the fraction of
276 symptomatic cases in the test-negative subpopulation, we obtain equation (1):

277
$$\psi_{adj} = 1 - \frac{\rho_c(1 - \rho_c)(\psi_c - 1 + \phi_c)(\alpha + \beta - 1)}{(\rho_c + \beta - 1)[\psi_c\rho_c(1 - \alpha) - \alpha(1 - \phi_c)(1 - \rho_c)]}$$

278

279

280 **ACKNOWLEDGEMENTS**

281 We thank Jeremie Guedj and Shreyas Joshi for helpful discussions. This study did not receive
282 any funding.

283

284 **AUTHOR CONTRIBUTIONS**

285 A.T. and N.M.D. designed the study and developed the mathematical formalism. A.T. collated
286 data from serosurveys, performed the analysis, and wrote the first draft. S.C., A.J., B.C. and
287 N.M.D. contributed to the analysis and edited the draft. A.T. and S.C. had access to all the data.
288 All authors approved the final draft and submission.

289

290 **COMPETING INTERESTS**

291 The authors declare that no competing interests exist.

292

293 **REFERENCES**

- 294 1. Johansson, M.A., Quandelacy, T.M., Kada, S., Prasad, P.V., Steele, M., Brooks, J.T.,
295 Slayton, R.B., Biggerstaff, M., and Butler, J.C. (2021). SARS-CoV-2 transmission from
296 people without COVID-19 symptoms. *JAMA Netw. Open* 4, e2035057.
297 10.1001/jamanetworkopen.2020.35057.
- 298 2. Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A.,
299 Subbarao, K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody
300 levels are highly predictive of immune protection from symptomatic SARS-CoV-2
301 infection. *Nat. Med.* 27, 1205-1211. 10.1038/s41591-021-01377-8.
- 302 3. Khoury, D.S., Docken, S.S., Subbarao, K., Kent, S.J., Davenport, M.P., and Cromer, D.
303 (2023). Predicting the efficacy of variant-modified COVID-19 vaccine boosters. *Nat. Med.*
304 29, 574-578. 10.1038/s41591-023-02228-4.
- 305 4. Padmanabhan, P., Desikan, R., and Dixit, N.M. (2022). Modeling how antibody responses
306 may determine the efficacy of COVID-19 vaccines. *Nat. Comput. Sci.* 2, 123-131.
307 10.1038/s43588-022-00198-0.
- 308 5. Oran, D.P., and Topol, E.J. (2021). The proportion of SARS-CoV-2 infections that are
309 asymptomatic : A systematic review. *Ann. Intern. Med.* 174, 655-662. 10.7326/M20-6976.
- 310 6. Sah, P., Fitzpatrick, M.C., Zimmer, C.F., Abdollahi, E., Juden-Kelly, L., Moghadas, S.M.,
311 Singer, B.H., and Galvani, A.P. (2021). Asymptomatic SARS-CoV-2 infection: A
312 systematic review and meta-analysis. *Proc. Natl. Acad. Sci. USA* 118, e2109229118.
313 doi:10.1073/pnas.2109229118.

- 314 7. Vos, E.R.A., den Hartog, G., Schepp, R.M., Kaaijk, P., van Vliet, J., Helm, K., Smits, G.,
315 Wijmenga-Monsuur, A., Verberk, J.D.M., van Boven, M., et al. (2020). Nationwide
316 seroprevalence of SARS-CoV-2 and identification of risk factors in the general population
317 of the Netherlands during the first epidemic wave. *J Epidemiol. Community Health* *75*,
318 489-495. [10.1136/jech-2020-215678](https://doi.org/10.1136/jech-2020-215678).
- 319 8. Sullivan, P.S., Siegler, A.J., Shioda, K., Hall, E.W., Bradley, H., Sanchez, T., Luisi, N.,
320 Valentine-Graves, M., Nelson, K.N., Fahimi, M., et al. (2022). Severe acute respiratory
321 syndrome coronavirus 2 cumulative incidence, United States, August 2020-December
322 2020. *Clin. Infect. Dis.* *74*, 1141-1150. [10.1093/cid/ciab626](https://doi.org/10.1093/cid/ciab626).
- 323 9. Chamberlain, A.T., Toomey, K.E., Bradley, H., Hall, E.W., Fahimi, M., Lopman, B.A., Luisi,
324 N., Sanchez, T., Drenzek, C., Shioda, K., et al. (2022). Cumulative incidence of SARS-
325 CoV-2 infections among adults in Georgia, United States, August to December 2020. *J.*
326 *Infect. Dis.* *225*, 396-403. [10.1093/infdis/jiab522](https://doi.org/10.1093/infdis/jiab522).
- 327 10. Menezes, A.M.B., Victora, C.G., Hartwig, F.P., Silveira, M.F., Horta, B.L., Barros, A.J.D.,
328 Mesenburg, M.A., Wehrmeister, F.C., Pellanda, L.C., Dellagostin, O.A., et al. (2021). High
329 prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2.
330 *Sci Rep* *11*, 13279. [10.1038/s41598-021-92775-y](https://doi.org/10.1038/s41598-021-92775-y).
- 331 11. Silva, A.A.M.D., Lima-Neto, L.G., Azevedo, C., Costa, L., Bragança, M., Barros Filho,
332 A.K.D., Wittlin, B.B., Souza, B.F., Oliveira, B., Carvalho, C.A., et al. (2020). Population-
333 based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhao.
334 *Rev. Saude Publica* *54*, 131. [10.11606/s1518-8787.2020054003278](https://doi.org/10.11606/s1518-8787.2020054003278).
- 335 12. Terças-Trettel, A.C.P., Muraro, A.P., Andrade, A.C.S., and Oliveira, E.C. (2022). Self-
336 reported symptoms and seroprevalence against SARS-CoV-2 in the population of Mato
337 Grosso: a household-based survey in 2020. *Rev. Assoc. Med. Bras.* (1992) *68*, 928-934.
338 [10.1590/1806-9282.20220078](https://doi.org/10.1590/1806-9282.20220078).
- 339 13. Albuquerque, J.O.M., Kamioka, G.A., Madalosso, G., Costa, S.A., Ferreira, P.B., Pino,
340 F.A., Sato, A.P.S., Carvalho, A.C.A., Amorim, A.B.P., Aires, C.C., et al. (2021). Prevalence
341 evolution of SARS-CoV-2 infection in the city of Sao Paulo, 2020-2021. *Rev. Saude*
342 *Publica* *55*, 62. [10.11606/s1518-8787.2021055003970](https://doi.org/10.11606/s1518-8787.2021055003970).
- 343 14. Nwosu, K., Fokam, J., Wanda, F., Mama, L., Orel, E., Ray, N., Meke, J., Tassegnig, A.,
344 Takou, D., Mimbe, E., et al. (2021). SARS-CoV-2 antibody seroprevalence and associated
345 risk factors in an urban district in Cameroon. *Nat. Commun.* *12*, 5851. [10.1038/s41467-
346 021-25946-0](https://doi.org/10.1038/s41467-021-25946-0).
- 347 15. Vial, P.A., González, C., Apablaza, M., Vial, C., Lavín, M.E., Araos, R., Rubilar, P., Icaza,
348 G., Florea, A., Pérez, C., et al. (2022). First wave of SARS-CoV-2 in Santiago Chile:
349 Seroprevalence, asymptomatic infection and infection fatality rate. *Epidemics* *40*, 100606.
350 [10.1016/j.epidem.2022.100606](https://doi.org/10.1016/j.epidem.2022.100606).
- 351 16. Vial, P., González, C., Icaza, G., Ramirez-Santana, M., Quezada-Gaete, R., Núñez-
352 Franz, L., Apablaza, M., Vial, C., Rubilar, P., Correa, J., et al. (2022). Seroprevalence,
353 spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of
354 Chile. *BMC Infect. Dis.* *22*, 99. [10.1186/s12879-022-07045-7](https://doi.org/10.1186/s12879-022-07045-7).
- 355 17. Li, Z., Guan, X., Mao, N., Luo, H., Qin, Y., He, N., Zhu, Z., Yu, J., Li, Y., Liu, J., et al.
356 (2021). Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected
357 provinces after containment of the first epidemic wave of COVID-19 in China. *Lancet Reg.*
358 *Health. West. Pac.* *8*, 100094. [10.1016/j.lanwpc.2021.100094](https://doi.org/10.1016/j.lanwpc.2021.100094).

- 359 18. Garay, E., Serrano-Coll, H., Rivero, R., Gastelbondo, B., Faccini-Martínez, A., Berrocal,
360 J., Pérez, A., Badillo, M., Martínez-Bravo, C., Botero, Y., et al. (2022). SARS-CoV-2 in
361 eight municipalities of the Colombian tropics: high immunity, clinical and
362 sociodemographic outcomes. *Trans. R. Soc. Trop. Med. Hyg.* *116*, 139-147.
363 10.1093/trstmh/trab094.
- 364 19. Serrano-Coll, H., Miller, H., Rodríguez-Van Der Hamen, C., Gastelbondo, B., Novoa, W.,
365 Oviedo, M., Rivero, R., Garay, E., and Mattar, S. (2021). High prevalence of SARS-CoV-
366 2 in an Indigenous community of the Colombian Amazon region. *Trop. Med. Infect. Dis.*
367 *6*. 10.3390/tropicalmed6040191.
- 368 20. Espenhain, L., Tribler, S., Svaerke Jørgensen, C., Holm Hansen, C., Wolff Sönksen, U.,
369 and Ethelberg, S. (2021). Prevalence of SARS-CoV-2 antibodies in Denmark: Nationwide,
370 population-based seroepidemiological study. *Eur. J. Epidemiol.* *36*, 715-725.
371 10.1007/s10654-021-00796-8.
- 372 21. Shaweno, T., Abdulhamid, I., Bezabih, L., Teshome, D., Derese, B., Tafesse, H., and
373 Shaweno, D. (2021). Seroprevalence of SARS-CoV-2 antibody among individuals aged
374 above 15 years and residing in congregate settings in Dire Dawa city administration,
375 Ethiopia. *Trop. Med. Health* *49*, 55. 10.1186/s41182-021-00347-7.
- 376 22. Carrat, F., de Lamballerie, X., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S.,
377 Renuy, A., Szabo de Edelenyi, F., Meyer, L., et al. (2021). Antibody status and cumulative
378 incidence of SARS-CoV-2 infection among adults in three regions of France following the
379 first lockdown and associated risk factors: a multicohort study. *Int. J. Epidemiol.* *50*, 1458-
380 1472. 10.1093/ije/dyab110.
- 381 23. Rouquette, A., Descarpentry, A., Dione, F., Falissard, B., Legleye, S., Vuillermoz, C.,
382 Pastorello, A., Meyer, L., Warszawski, J., Davisse-Paturet, C., et al. (2023). Comparison
383 of depression and anxiety following self-reported COVID-19-like symptoms vs SARS-
384 CoV-2 seropositivity in France. *JAMA Netw. Open* *6*, e2312892.
385 10.1001/jamanetworkopen.2023.12892.
- 386 24. Beaumont, A., Durand, C., Ledrans, M., Schwoebel, V., Noel, H., Le Strat, Y., Diulius, D.,
387 Colombain, L., Médus, M., Gueudet, P., et al. (2021). Seroprevalence of anti-SARS-CoV-
388 2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in
389 France: A cross-sectional study. *BMJ Open* *11*, e053201. 10.1136/bmjopen-2021-053201.
- 390 25. Santos-Hövenner, C., Neuhauser, H.K., Rosario, A.S., Busch, M., Schlaud, M., Hoffmann,
391 R., Gößwald, A., Koschollek, C., Hoebel, J., Allen, J., et al. (2020). Serology- and PCR-
392 based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained
393 early hotspot (CoMoLo study), Germany, May to June 2020. *Euro. Surveill.* *25*.
394 10.2807/1560-7917.ES.2020.25.47.2001752.
- 395 26. Weis, S., Scherag, A., Baier, M., Kiehntopf, M., Kamradt, T., Kolanos, S., Ankert, J.,
396 Glöckner, S., Makarewicz, O., Hagel, S., et al. (2021). Antibody response using six
397 different serological assays in a completely PCR-tested community after a coronavirus
398 disease 2019 outbreak-the CoNAN study. *Clin. Microbiol. Infect.* *27*, 470 e471-470 e479.
399 10.1016/j.cmi.2020.11.009.
- 400 27. Merkely, B., Szabó, A.J., Kosztin, A., Berényi, E., Sebestyén, A., Lengyel, C., Merkely, G.,
401 Karády, J., Várkonyi, I., Papp, C., et al. (2020). Novel coronavirus epidemic in the
402 Hungarian population, a cross-sectional nationwide survey to support the exit policy in
403 Hungary. *Geroscience* *42*, 1063-1074. 10.1007/s11357-020-00226-9.

- 404 28. Murhekar, M.V., Bhatnagar, T., Selvaraju, S., Saravanakumar, V., Thangaraj, J.W.V.,
405 Shah, N., Kumar, M.S., Rade, K., Sabarinathan, R., Asthana, S., et al. (2021). SARS-
406 CoV-2 antibody seroprevalence in India, August-September, 2020: Findings from the
407 second nationwide household serosurvey. *Lancet Glob. Health* 9, e257-e266.
408 10.1016/S2214-109X(20)30544-1.
- 409 29. Selvaraju, S., Kumar, M.S., Thangaraj, J.W.V., Bhatnagar, T., Saravanakumar, V., Kumar,
410 C.P.G., Sekar, K., Ilayaperumal, E., Sabarinathan, R., Jagadeesan, M., et al. (2021).
411 Population-based serosurvey for severe acute respiratory syndrome coronavirus 2
412 transmission, Chennai, India. *Emerg. Infect. Dis.* 27, 586-589. 10.3201/eid2702.203938.
- 413 30. Kumar, D., Sidhu, M., Dogra, S., Kumar, B., Sahni, B., Yadav, A.K., Bala, K., Kumari, R.,
414 Mahajan, R., Bavoria, S., et al. (2022). Seroprevalence of anti SARS-CoV-2 IgG
415 antibodies among adults in Jammu district, India: A community-based study. *Indian J.*
416 *Med. Res.* 155, 171-177. 10.4103/ijmr.IJMR_4489_20.
- 417 31. Khan, S.M.S., Qurieshi, M.A., Haq, I., Majid, S., Ahmad, J., Ayub, T., Bhat, A.A., Fazili,
418 A.B., Ganai, A.M., Jan, Y., et al. (2021). Seroprevalence of SARS-CoV-2-specific IgG
419 antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results
420 of a population-based seroprevalence survey from October to November 2020. *BMJ*
421 *Open* 11, e053791. 10.1136/bmjopen-2021-053791.
- 422 32. Poustchi, H., Darvishian, M., Mohammadi, Z., Shayanrad, A., Delavari, A.,
423 Bahadorimonfared, A., Eslami, S., Javanmard, S.H., Shakiba, E., Somi, M.H., et al.
424 (2021). SARS-CoV-2 antibody seroprevalence in the general population and high-risk
425 occupational groups across 18 cities in Iran: a population-based cross-sectional study.
426 *Lancet Infect. Dis.* 21, 473-481. 10.1016/S1473-3099(20)30858-6.
- 427 33. Heavey, L., Garvey, P., Colgan, A.M., Thornton, L., Connell, J., Roux, T., Hunt, M.,
428 O'Callaghan, F., Culkinn, F., Keogan, M., et al. (2021). The study to investigate COVID-19
429 infection in people living in Ireland (SCOPI): A seroprevalence study, June to July 2020.
430 *Euro Surveill.* 26, 2001741. doi:[https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2021.26.48.2001741)
431 [7917.ES.2021.26.48.2001741](https://doi.org/10.2807/1560-7917.ES.2021.26.48.2001741).
- 432 34. Pagani, G., Giacomelli, A., Conti, F., Bernacchia, D., Rondanin, R., Prina, A., Scolari, V.,
433 Rizzo, A., Beltrami, M., Caimi, C., et al. (2021). Prevalence of SARS-CoV-2 in an area of
434 unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda,
435 Italy. *PLoS One* 16, e0246513. 10.1371/journal.pone.0246513.
- 436 35. Stefanelli, P., Bella, A., Fedele, G., Pancheri, S., Leone, P., Vacca, P., Neri, A.,
437 Carannante, A., Fazio, C., Benedetti, E., et al. (2021). Prevalence of SARS-CoV-2 IgG
438 antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a
439 population-based study. *Clin. Microbiol. Infect.* 27, 633 e631-633 e637.
440 10.1016/j.cmi.2020.11.013.
- 441 36. Abdul-Raheem, R., Moosa, S., Waheed, F., Aboobakuru, M., Ahmed, I.N., Rafeeg, F.N.,
442 and Saeed, M. (2021). A sero-epidemiological study after two waves of the COVID-19
443 epidemic. *Asian Pac. J. Allergy Immunol.* 10.12932/AP-040721-1177.
- 444 37. Sagara, I., Woodford, J., Kone, M., Assadou, M.H., Katile, A., Attaher, O., Zeguime, A.,
445 Doucoure, M., Higbee, E., Lane, J., et al. (2022). Rapidly increasing severe acute
446 respiratory syndrome coronavirus 2 seroprevalence and limited clinical disease in 3
447 Malian communities: A prospective cohort study. *Clin. Infect. Dis.* 74, 1030-1038.
448 10.1093/cid/ciab589.

- 449 38. Basto-Abreu, A., Carnalla, M., Torres-Ibarra, L., Romero-Martínez, M., Martínez-
450 Barnetche, J., Lopez-Martínez, I., Aparicio-Antonio, R., Shamah-Levy, T., Alpuche-
451 Aranda, C., Rivera, J.A., et al. (2022). Nationally representative SARS-CoV-2 antibody
452 prevalence estimates after the first epidemic wave in Mexico. *Nat. Commun.* *13*, 589.
453 [10.1038/s41467-022-28232-9](https://doi.org/10.1038/s41467-022-28232-9).
- 454 39. Arnaldo, P., Mabunda, N., Young, P.W., Tran, T., Siteo, N., Chelene, I., Nhanombe, A.,
455 Ismael, N., Júnior, A., Cubula, B., et al. (2022). Prevalence of severe acute respiratory
456 syndrome coronavirus 2 (SARS-CoV-2) antibodies in the Mozambican population: A
457 cross-sectional serologic study in 3 cities, July-August 2020. *Clin. Infect. Dis.* *75*, S285-
458 S293. [10.1093/cid/ciac516](https://doi.org/10.1093/cid/ciac516).
- 459 40. Okpala, O.V., Dim, C.C., Ugwu, C.I., Onyemaechi, S., Uchebo, O., Chukwulobelu, U.,
460 Emembolu, C., Okoye, B., Igboekwu, C., Okoye, U.B., et al. (2021). Population
461 seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria. *Int. J.*
462 *Infect. Dis.* *110*, 171-178. [10.1016/j.ijid.2021.07.040](https://doi.org/10.1016/j.ijid.2021.07.040).
- 463 41. Nisar, M.I., Ansari, N., Khalid, F., Amin, M., Shahbaz, H., Hotwani, A., Rehman, N., Pugh,
464 S., Mehmood, U., Rizvi, A., et al. (2021). Serial population-based serosurveys for COVID-
465 19 in two neighbourhoods of Karachi, Pakistan. *Int. J. Infect. Dis.* *106*, 176-182.
466 [10.1016/j.ijid.2021.03.040](https://doi.org/10.1016/j.ijid.2021.03.040).
- 467 42. Huamaní, C., Velásquez, L., Montes, S., Mayanga-Herrera, A., and Bernabé-Ortiz, A.
468 (2021). SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: adult population-
469 based cross-sectional study. *PeerJ* *9*, e12149. [10.7717/peerj.12149](https://doi.org/10.7717/peerj.12149).
- 470 43. Díaz-Vélez, C., Failoc-Rojas, V.E., Valladares-Garrido, M.J., Colchado, J., Carrera-
471 Acosta, L., Becerra, M., Moreno Paico, D., and Ocampo-Salazar, E.T. (2021). SARS-CoV-
472 2 seroprevalence study in Lambayeque, Peru. June-July 2020. *PeerJ* *9*, e11210.
473 [10.7717/peerj.11210](https://doi.org/10.7717/peerj.11210).
- 474 44. Reyes-Vega, M.F., Soto-Cabezas, M.G., Cárdenas, F., Martel, K.S., Valle, A., Valverde,
475 J., Vidal-Anzardo, M., Falcón, M.E., Munayco, C.V., and Peru COVID-19 Working Group
476 (2021). SARS-CoV-2 prevalence associated to low socioeconomic status and
477 overcrowding in an LMIC megacity: A population-based seroepidemiological survey in
478 Lima, Peru. *EClinicalMedicine* *34*, 100801. [10.1016/j.eclinm.2021.100801](https://doi.org/10.1016/j.eclinm.2021.100801).
- 479 45. Moyano, L.M., Toledo, A.K., Chirinos, J., Vilchez Barreto, P.M.Q., Cavalcanti, S., Gamboa,
480 R., Ypanaque, J., Meza, M., Noriega, S., Herrera, V., et al. (2023). SARS-CoV-2
481 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave.
482 *PLoS Negl. Trop. Dis.* *17*, e0010794. [10.1371/journal.pntd.0010794](https://doi.org/10.1371/journal.pntd.0010794).
- 483 46. Canto e Castro, L., Pereira, A.H.G., Ribeiro, R., Alves, C., Veloso, L., Vicente, V., Alves,
484 D., Domingues, I., Silva, C., Gomes, A., et al. (2021). Prevalence of SARS-CoV-2
485 antibodies after first 6 months of COVID-19 pandemic, Portugal. *Emerg. Infect. Dis.* *27*,
486 2878. [10.3201/eid2711.210636](https://doi.org/10.3201/eid2711.210636).
- 487 47. Kislaya, I., Gonçalves, P., Barreto, M., Sousa, R., Garcia, A.C., Matos, R., Guiomar, R.,
488 Rodrigues, A.P., and on Behalf of ISNCOVID-19 Group (2021). Seroprevalence of SARS-
489 CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological
490 Survey (ISNCOVID-19). *Acta Med. Port.* *34*, 87-94. [10.20344/amp.15122](https://doi.org/10.20344/amp.15122).
- 491 48. Talla, C., Loucoubar, C., Roka, J.L., Barry, M.A., Ndiaye, S., Diarra, M., Thiam, M.S.,
492 Faye, O., Dia, M., Diop, M., et al. (2022). Seroprevalence of anti-SARS-CoV-2 antibodies
493 in Senegal: a national population-based cross-sectional survey, between October and
494 November 2020. *IJID Reg* *3*, 117-125. [10.1016/j.ijregi.2022.02.007](https://doi.org/10.1016/j.ijregi.2022.02.007).

- 495 49. Karachaliou, M., Moncunill, G., Espinosa, A., Castano-Vinyals, G., Jiménez, A., Vidal, M.,
496 Santano, R., Barrios, D., Puyol, L., Carreras, A., et al. (2021). Infection induced SARS-
497 CoV-2 seroprevalence and heterogeneity of antibody responses in a general population
498 cohort study in Catalonia Spain. *Sci. Rep.* *11*, 21571. [10.1038/s41598-021-00807-4](https://doi.org/10.1038/s41598-021-00807-4).
- 499 50. Pérez-Gómez, B., Pastor-Barriuso, R., Pérez-Olmeda, M., Hernán, M.A., Oteo-Iglesias,
500 J., Fernández de Larrea, N., Fernández-García, A., Martín, M., Fernández-Navarro, P.,
501 Cruz, I., et al. (2021). ENE-COVID nationwide serosurvey served to characterize
502 asymptomatic infections and to develop a symptom-based risk score to predict COVID-
503 19. *J. Clin. Epidemiol.* *139*, 240-254. [10.1016/j.jclinepi.2021.06.005](https://doi.org/10.1016/j.jclinepi.2021.06.005).
- 504 51. Richard, A., Wisniak, A., Perez-Saez, J., Garrison-Desany, H., Petrovic, D., Piumatti, G.,
505 Baysson, H., Picazio, A., Pennacchio, F., De Ridder, D., et al. (2022). Seroprevalence of
506 anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in
507 Geneva, Switzerland: a population-based study. *Scand. J. Public Health* *50*, 124-135.
508 [10.1177/14034948211048050](https://doi.org/10.1177/14034948211048050).
- 509 52. Alsuwaidi, A.R., Al Hosani, F.I., Al Memari, S., Narchi, H., Abdel Wareth, L., Kamal, H., Al
510 Ketbi, M., Al Baloushi, D., Elfateh, A., Khudair, A., et al. (2021). Seroprevalence of COVID-
511 19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-
512 sectional study. *Int. J. Epidemiol.* *50*, 1077-1090. [10.1093/ije/dyab077](https://doi.org/10.1093/ije/dyab077).
- 513 53. Lamba, K., Bradley, H., Shioda, K., Sullivan, P.S., Luisi, N., Hall, E.W., Mehrotra, M.L.,
514 Lim, E., Jain, S., Kamali, A., et al. (2021). SARS-CoV-2 cumulative incidence and period
515 seroprevalence: Results from a statewide population-based serosurvey in California.
516 *Open Forum Infect. Dis.* *8*, ofab379. [10.1093/ofid/ofab379](https://doi.org/10.1093/ofid/ofab379).
- 517 54. Pathela, P., Crawley, A., Weiss, D., Maldin, B., Cornell, J., Purdin, J., Schumacher, P.K.,
518 Marovich, S., Li, J., Daskalakis, D., and NYC Serosurvey Team (2021). Seroprevalence
519 of severe acute respiratory syndrome coronavirus 2 following the largest initial epidemic
520 wave in the United States: Findings from New York City, 13 May to 21 July 2020. *J. Infect.*
521 *Dis.* *224*, 196-206. [10.1093/infdis/jiab200](https://doi.org/10.1093/infdis/jiab200).
- 522 55. Kumar, M.S., Thangaraj, J.W.V., Saravanakumar, V., Selvaraju, S., Kumar, C.P.G.,
523 Sabarinathan, R., Jagadeesan, M., Hemalatha, M.S., Rani, D.S., Jeyakumar, A., et al.
524 (2021). Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and
525 October 2020. *Trans. R. Soc. Trop. Med. Hyg.* *115*, 1350-1352. [10.1093/trstmh/trab136](https://doi.org/10.1093/trstmh/trab136).
- 526 56. Sharma, N., Sharma, P., Basu, S., Saxena, S., Chawla, R., Dushyant, K., Mundeja, N.,
527 Marak, Z., Singh, S., Singh, G., and Rustagi, R. (2022). The seroprevalence of severe
528 acute respiratory syndrome coronavirus 2 in Delhi, India: a repeated population-based
529 seroepidemiological study. *Trans. R. Soc. Trop. Med. Hyg.* *116*, 242-251.
530 [10.1093/trstmh/trab109](https://doi.org/10.1093/trstmh/trab109).
- 531 57. Meyerowitz, E.A., Richterman, A., Bogoch, II, Low, N., and Cevik, M. (2021). Towards an
532 accurate and systematic characterisation of persistently asymptomatic infection with
533 SARS-CoV-2. *Lancet Infect. Dis.* *21*, e163-e169. [10.1016/S1473-3099\(20\)30837-9](https://doi.org/10.1016/S1473-3099(20)30837-9).
- 534 58. Ioannidis, J.P.A. (2021). Infection fatality rate of COVID-19 inferred from seroprevalence
535 data. *Bull. World Health Organ.* *99*, 19-33F. [10.2471/BLT.20.265892](https://doi.org/10.2471/BLT.20.265892).
- 536 59. Wallis, S. (2013). Binomial confidence intervals and contingency tests: Mathematical
537 fundamentals and the evaluation of alternative methods. *J. Quant. Linguistics* *20*, 178-
538 208. [10.1080/09296174.2013.799918](https://doi.org/10.1080/09296174.2013.799918).
- 539 60. Rogan, W.J., and Gladen, B. (1978). Estimating prevalence from the results of a
540 screening test. *Amer. J. Epidemiol.* *107*, 71-76. [10.1093/oxfordjournals.aje.a112510](https://doi.org/10.1093/oxfordjournals.aje.a112510).

- 541 61. Leung, N.H.L., Xu, C., Ip, D.K.M., and Cowling, B.J. (2015). Review article: The fraction
542 of influenza virus infections that are asymptomatic: A Systematic review and meta-
543 analysis. *Epidemiology* 26, 862-872. [10.1097/ede.0000000000000340](https://doi.org/10.1097/ede.0000000000000340).
- 544 62. Wang, T.E., Lin, C.Y., King, C.C., and Lee, W.C. (2010). Estimating pathogen-specific
545 asymptomatic ratios. *Epidemiology* 21, 726-728. [10.1097/EDE.0b013e3181e94274](https://doi.org/10.1097/EDE.0b013e3181e94274).
- 546 63. Buitrago-Garcia, D., Egli-Gany, D., Counotte, M.J., Hossmann, S., Imeri, H., Ipekci, A.M.,
547 Salanti, G., and Low, N. (2020). Occurrence and transmission potential of asymptomatic
548 and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-
549 analysis. *PLoS Med.* 17, e1003346.
- 550 64. Bertozzi, A.L., Franco, E., Mohler, G., Short, M.B., and Sledge, D. (2020). The challenges
551 of modeling and forecasting the spread of COVID-19. *Proc. Natl. Acad. Sci. USA* 117,
552 16732-16738. doi:10.1073/pnas.2006520117.
- 553 65. Loo, S.L., Howerton, E., Contamin, L., Smith, C.P., Borchering, R.K., Mullany, L.C., Bents,
554 S., Carcelen, E., Jung, S.-m., Bogich, T., et al. (2024). The US COVID-19 and Influenza
555 Scenario Modeling Hubs: Delivering long-term projections to guide policy. *Epidemics* 46,
556 100738. <https://doi.org/10.1016/j.epidem.2023.100738>.
- 557 66. Kissler, S.M., Tedijanto, C., Goldstein, E., Grad, Y.H., and Lipsitch, M. (2020). Projecting
558 the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*
559 368, 860-868. doi:10.1126/science.abb5793.
- 560 67. Zhu, C., Pang, S., Liu, J., and Duan, Q. (2024). Current progress, challenges and
561 prospects in the development of COVID-19 vaccines. *Drugs* 84, 403-423.
562 [10.1007/s40265-024-02013-8](https://doi.org/10.1007/s40265-024-02013-8).
- 563 68. Augusto, D.G., Murdolo, L.D., Chatzileontiadou, D.S., Sabatino Jr, J.J., Yusufali, T.,
564 Peyser, N.D., Butcher, X., Kizer, K., Guthrie, K., and Murray, V.W. (2023). A common allele
565 of HLA is associated with asymptomatic SARS-CoV-2 infection. *Nature* 620, 128–136.
566 <https://doi.org/10.1038/s41586-023-06331-x>.
- 567 69. Marchal, A., Cirulli, E.T., Neveux, I., Bellos, E., Thwaites, R.S., Barrett, K.M.S., Zhang, Y.,
568 Nemes-Bokun, I., Kalinova, M., and Catchpole, A. (2024). Lack of association between
569 classical HLA genes and asymptomatic SARS-CoV-2 infection. *HGG Adv.* 5, 100300.
570 [10.1016/j.xhgg.2024.100300](https://doi.org/10.1016/j.xhgg.2024.100300).
- 571 70. Chowdhury, S., Tiwari, A., James, A., Chatterjee, B., and Dixit, N.M. (2023). Asymptomatic
572 SARS-CoV-2 infections tend to occur less frequently in developed nations. medRxiv,
573 2023.2012.2014.23299954. [10.1101/2023.12.14.23299954](https://doi.org/10.1101/2023.12.14.23299954).
- 574 71. Owens, K., Esmaeili, S., and Schiffer, J.T. (2024). Heterogeneous SARS-CoV-2 kinetics
575 due to variable timing and intensity of immune responses. *JCI Insight* 9, e176286.
576 [10.1172/jci.insight.176286](https://doi.org/10.1172/jci.insight.176286).
- 577 72. Chatterjee, B., Singh Sandhu, H., and Dixit, N.M. (2022). Modeling recapitulates the
578 heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the
579 innate immune and CD8 T-cell responses between patients experiencing mild and severe
580 symptoms. *PLoS Pathog.* 18, e1010630.
- 581 73. Pawlowski, C., Silvert, E., O'Horo, J.C., Lenehan, P.J., Challener, D., Gnass, E.,
582 Murugadoss, K., Ross, J., Speicher, L., Geyer, H., et al. (2022). SARS-CoV-2 and
583 influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection
584 rates, cohort characteristics, and clinical outcomes. *PNAS Nexus* 1,
585 [10.1093/pnasnexus/pgac071](https://doi.org/10.1093/pnasnexus/pgac071).

- 586 74. Almadhoon, H.W., Hamdallah, A., Elsayed, S.M., Hagrass, A.I., Hasan, M.T., Fayoud,
587 A.M., Al-Kafarna, M., Elbahnasawy, M., Alqatati, F., Ragab, K.M., et al. (2022). The effect
588 of influenza vaccine in reducing the severity of clinical outcomes in patients with COVID-
589 19: a systematic review and meta-analysis. *Sci. Rep.* 12, 14266. [10.1038/s41598-022-](https://doi.org/10.1038/s41598-022-18618-6)
590 [18618-6](https://doi.org/10.1038/s41598-022-18618-6).

591